vs
Side-by-side financial comparison of GERON CORP (GERN) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $47.2M, roughly 1.0× GERON CORP). IRONWOOD PHARMACEUTICALS INC runs the higher net margin — -4.8% vs -39.0%, a 34.2% gap on every dollar of revenue. On growth, GERON CORP posted the faster year-over-year revenue change (67.1% vs -47.3%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs -20.2%).
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
GERN vs IRWD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $47.7M |
| Net Profit | $-18.4M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | -29.4% | 14.3% |
| Net Margin | -39.0% | -4.8% |
| Revenue YoY | 67.1% | -47.3% |
| Net Profit YoY | 30.3% | -200.9% |
| EPS (diluted) | $-0.03 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.7M | ||
| Q3 25 | $47.2M | $122.1M | ||
| Q2 25 | $49.0M | $85.2M | ||
| Q1 25 | $39.6M | $41.1M | ||
| Q4 24 | — | $90.5M | ||
| Q3 24 | $28.3M | $91.6M | ||
| Q2 24 | $882.0K | $94.4M | ||
| Q1 24 | $304.0K | $74.9M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $-18.4M | $40.1M | ||
| Q2 25 | $-16.4M | $23.6M | ||
| Q1 25 | $-19.8M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-26.4M | $3.6M | ||
| Q2 24 | $-67.4M | $-860.0K | ||
| Q1 24 | $-55.4M | $-4.2M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | -29.4% | 61.8% | ||
| Q2 25 | -25.4% | 53.2% | ||
| Q1 25 | -42.2% | -70.7% | ||
| Q4 24 | — | 34.8% | ||
| Q3 24 | -99.8% | 28.0% | ||
| Q2 24 | -7860.9% | 26.5% | ||
| Q1 24 | -18465.1% | 14.7% |
| Q4 25 | — | -4.8% | ||
| Q3 25 | -39.0% | 32.8% | ||
| Q2 25 | -33.4% | 27.7% | ||
| Q1 25 | -50.1% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | -93.5% | 4.0% | ||
| Q2 24 | -7639.8% | -0.9% | ||
| Q1 24 | -18220.4% | -5.6% |
| Q4 25 | — | $0.01 | ||
| Q3 25 | $-0.03 | $0.23 | ||
| Q2 25 | $-0.02 | $0.14 | ||
| Q1 25 | $-0.03 | $-0.23 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | $-0.04 | $0.02 | ||
| Q2 24 | $-0.10 | $-0.01 | ||
| Q1 24 | $-0.09 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.1M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $248.7M | $-261.8M |
| Total Assets | $567.4M | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $215.5M | ||
| Q3 25 | $78.1M | $140.4M | ||
| Q2 25 | $77.7M | $92.9M | ||
| Q1 25 | $83.7M | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | $60.3M | $88.2M | ||
| Q2 24 | $116.9M | $105.5M | ||
| Q1 24 | $189.8M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | — | $-261.8M | ||
| Q3 25 | $248.7M | $-264.2M | ||
| Q2 25 | $259.5M | $-308.2M | ||
| Q1 25 | $268.2M | $-334.1M | ||
| Q4 24 | — | $-301.3M | ||
| Q3 24 | $292.3M | $-311.3M | ||
| Q2 24 | $306.7M | $-321.7M | ||
| Q1 24 | $344.9M | $-330.5M |
| Q4 25 | — | $396.9M | ||
| Q3 25 | $567.4M | $396.1M | ||
| Q2 25 | $555.2M | $342.9M | ||
| Q1 25 | $562.5M | $327.2M | ||
| Q4 24 | — | $350.9M | ||
| Q3 24 | $444.9M | $389.5M | ||
| Q2 24 | $449.4M | $395.6M | ||
| Q1 24 | $482.1M | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.6M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $74.6M | ||
| Q3 25 | $-13.6M | $47.6M | ||
| Q2 25 | $-27.4M | $-15.1M | ||
| Q1 25 | $-48.0M | $20.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | $-58.9M | $9.9M | ||
| Q2 24 | $-53.5M | $33.5M | ||
| Q1 24 | $-62.3M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | $-53.7M | $33.4M | ||
| Q1 24 | $-62.9M | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | -6086.6% | 35.4% | ||
| Q1 24 | -20680.3% | 60.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 23.4% | 0.1% | ||
| Q1 24 | 202.3% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | -0.64× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | — | 2.71× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
